

Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on April 2, 2026 | For discussion with your oncologist

TRIAL

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

NCT ID: NCT05077280 Phase: PHASE2 Sponsor: California Pacific Medical Center Research Institute Status: Unknown

SUMMARY

This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with immunotherapy with relatlimab and nivolumab for up to two years. SBRT will be given in three doses of 15Gy each to 1-5 separate metastases. Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years

KEY ELIGIBILITY CRITERIA

- * measurable metastatic uveal melanoma.
- * No concomitant therapy.
- * Prior PD1 or tebendafesp allowed.
- * Performance status 0-1.
- * No active Hepatitis B.
- * No known HIV infection.
- * WBC >2000 , ANC >1500 , Hgb >8 .
- * Creatinine $< 3 \times$ ULN.
- * AST & ALT $< 2.5 \times$ ULN Bilirubin $< 2 \times$ ULN.
- * Albumin >2.9

ENROLLMENT CONTACT

Madeline Decker

California Pacific Medical Center Research Institute
San Francisco, California, United States
Phone: 415-600-3613
Email: KimB@sutterhealth.org

Total sites: 1 | 1 currently recruiting